Results 271 to 280 of about 119,519 (336)

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Letter to the editor regarding to 'cardiovascular safety of janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis'. [PDF]

Ann Med
Liu S, Zhang L.
europepmc   +1 more source

Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis [PDF]

Peter Youssef, Sabina Ciciriello, Talib Tahir, Joanna Leadbetter, Belinda Butcher, Miriam Calao, Nicole C. Walsh, Catherine O’Sullivan, Tegan Smith, Geoffrey Littlejohn   +9 more
openalex   +1 more source

Signal Transducer and Activator of Transcription (STAT) Proteins Regulate Mucosal‐Associated Invariant T (MAIT) Cell Function

Immunology, EarlyView.
Integrated transcriptomic, proteomic and flow cytometry analyses reveal that STAT1 negatively regulates MAIT cell effector and glycolytic functions, while STAT3, STAT5 and HIF1α act as positive modulators. Targeting these pathways may offer new strategies to restore MAIT cell function in immune dysregulation and cancer.
Olivia J. Cheng, Eimear K. Ryan, Michael Bennett, Christy Clutter, Jackson G. Cacioppo, Jeffrey Aubé, Andy E. Hogan, Daniel T. Leung   +7 more
wiley   +1 more source

Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers. [PDF]

Rheumatology (Oxford)
Sherman MA, Nicolai R, Datyner EK, Rosina S, Hamilton A, Ardalan K, Bader-Meunier B, Brown AG, Jansen MHA, Kim S, Lang B, Campanilho-Marques R, McCann LJ, Sanner H, Veldkamp SR, Wilkinson MGL, Yi BY, Kim H, Tarvin SE, Papadopoulou C, CARRA JDM Therapeutics Workgroup and the PReS JDM Working Party .   +20 more
europepmc   +1 more source

Current indications for the use of Janus kinase inhibitors in the treatment of juvenile idiopathic arthritis

Violetta Opoka‐Winiarska, Elżbieta Smolewska   +1 more
openalex   +2 more sources

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I. Silverberg, Kim A. Papp, Diamant Thaçi, Marjolein S. De Bruin‐Weller, Adam Reich, Ketty Peris, Kirk Barber, Ryszard Galus, Andrzej Kaszuba, Matthew Zirwas, Walter K. Nahm, Gretel Trullenque, Laura Maintz, Sady Alpizar, Sang Wook Son, Vivian Laquer, Linda Stein Gold, Soo Yeon Cheong, Anna Ryzhkova, Agnes Drahos, Liliana Ulianov, Christophe Piketty   +24 more
wiley   +1 more source

Correction to: Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study. [PDF]

Calcif Tissue Int
Schulz N, Asendorf T, van Wijnen P, Wilhelmi T, Müller-Ladner U, Lange U, Klemm P.   +6 more
europepmc   +1 more source

Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study

International Journal of Dermatology, EarlyView.
Mattia Cristallo, Ippolita Zaza, Michelina Francesca Daddato, Loredana Muolo, Francesco Pugliese, Alice D'Amico, Marco Casciaro, Sebastiano Gangemi, Eustachio Nettis   +8 more
wiley   +1 more source

Therapeutic advances in pruritus as a model of personalized medicine

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung, Ramsey Kubofcik, Brian S. Kim   +2 more
wiley   +1 more source